MP14-02 ROLE OF [18F] FLUORODEOXYGLUCOSE-PET IN DIFFERENTIATING PAPILLARY RENAL CELL CARCINOMA FROM CLEAR CELL RENAL CELL CARCINOMA AND ONCOCYTOMA

医学 嗜酸细胞瘤 肾细胞癌 肾嗜酸细胞瘤 乳头状肾细胞癌 肾透明细胞癌 清除单元格 透明细胞癌 病理 放射科
作者
Moozhan Nikpanah,Mark A. Ahlman,A. Cahid Civelek,S. Mojdeh Mirmomen,Xiaobai Li,Anna K. Paschall,Ramaprasad Srinivasan,Faraz Farhadi,W. Marston Linehan,Ashkan A. Malayeri
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:199 (4S)
标识
DOI:10.1016/j.juro.2018.02.495
摘要

You have accessJournal of UrologyImaging/Radiology: Uroradiology I1 Apr 2018MP14-02 ROLE OF [18F] FLUORODEOXYGLUCOSE-PET IN DIFFERENTIATING PAPILLARY RENAL CELL CARCINOMA FROM CLEAR CELL RENAL CELL CARCINOMA AND ONCOCYTOMA Moozhan Nikpanah, Mark A. Ahlman, A. Cahid Civelek, S. Mojdeh Mirmomen, Xiaobai Li, Anna K. Paschall, Ramaprasad Srinivasan, Faraz Farhadi, W. Marston Linehan, and Ashkan A. Malayeri Moozhan NikpanahMoozhan Nikpanah More articles by this author , Mark A. AhlmanMark A. Ahlman More articles by this author , A. Cahid CivelekA. Cahid Civelek More articles by this author , S. Mojdeh MirmomenS. Mojdeh Mirmomen More articles by this author , Xiaobai LiXiaobai Li More articles by this author , Anna K. PaschallAnna K. Paschall More articles by this author , Ramaprasad SrinivasanRamaprasad Srinivasan More articles by this author , Faraz FarhadiFaraz Farhadi More articles by this author , W. Marston LinehanW. Marston Linehan More articles by this author , and Ashkan A. MalayeriAshkan A. Malayeri More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.495AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We assessed differences in [18F] fluorodeoxyglucose (FDG) PET-derived standardized uptake value (SUV) of renal neoplasms, including papillary renal cell carcinoma (pRCC) type 1 and 2, clear cell renal cell carcinoma (ccRCC) and oncocytoma. METHODS In this retrospective study, 100 pathology proven renal lesions (25 pRCC type 1, 8 pRCC type 2, 57 ccRCC, 10 oncocytoma) that met our inclusion criteria (size ≥1cm, timeframe between the preoperative FDG PET/CT performed and surgery ≤18 months) were selected from 35 patients. Renal lesions with distant metastasis were identified. Two nuclear medicine specialists, blinded to clinical information, independently reviewed FDG-PET/CT images. With care to avoid urinary FDG activity, lesional SUV mean was determined and target to background ratio respective to liver (TBRLiver) was calculated. Intrarater reliability score was calculated by using unweighted k statistics to measure agreement between the readers. Values were averaged to a single measurement for each lesion. Linear mixed model was used to compare TBRLiver values among four categories of neoplasm. The model accounted for within-patient correlation and metastatic or non-metastatic designation of the lesions. RESULTS The 100 renal lesions were selected from 35 patients (24 male and 11 female, mean age: 54). Metastatic lesions included 9 pRCC type 1, 4 pRCC type 2, and 11 ccRCC. Intrarater reliability test resulted in a mean k score of 0.86. Median TBRLiver value (interquartile range) was 1.23 (0.53, 5.04) for pRCC type 1, 3.78 (0.49, 8.46) for pRCC type 2, 0.94 (0.41,2.21) for ccRCC, and 0.99 (0.63,1.41) for oncocytoma. The mixed model showed a significant difference in TBRLiver value among four categories (p=0.0003). Pairwise comparison showed significant difference in TBRLiver value between ccRCC and pRCC type 2 (p<0.0001), pRCC type 1 and pRCC type 2 (p=0.01), and oncocytoma and pRCC type 2 (p=0.025). CONCLUSIONS Papillary type 2 of renal cell carcinoma has higher FDG activity than clear cell RCC, papillary type 1 RCC, and oncocytoma. These findings are important to help determine if an imaging biomarker such as FDG is useful to study the genetic-metabolic linkages and clinical applicability in renal neoplasms. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e179-e180 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Moozhan Nikpanah More articles by this author Mark A. Ahlman More articles by this author A. Cahid Civelek More articles by this author S. Mojdeh Mirmomen More articles by this author Xiaobai Li More articles by this author Anna K. Paschall More articles by this author Ramaprasad Srinivasan More articles by this author Faraz Farhadi More articles by this author W. Marston Linehan More articles by this author Ashkan A. Malayeri More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷傲的无颜完成签到 ,获得积分10
1秒前
1秒前
文艺问凝完成签到,获得积分10
2秒前
3秒前
难过橘子完成签到,获得积分10
3秒前
大模型应助Leoon采纳,获得30
3秒前
兔子发布了新的文献求助10
4秒前
4秒前
Joker发布了新的文献求助30
4秒前
扶溪筠完成签到,获得积分10
4秒前
5秒前
5秒前
Alien发布了新的文献求助10
6秒前
8秒前
8秒前
超级砖家发布了新的文献求助10
8秒前
22发布了新的文献求助10
9秒前
lxu110发布了新的文献求助10
9秒前
汉堡包应助雪宝采纳,获得10
10秒前
马敬丽发布了新的文献求助10
10秒前
木昆完成签到 ,获得积分10
10秒前
11秒前
桐桐应助Xu采纳,获得10
11秒前
12秒前
12秒前
asa发布了新的文献求助10
13秒前
听雨的猫完成签到 ,获得积分10
13秒前
14秒前
黑米粥发布了新的文献求助200
14秒前
红雨灰衣发布了新的文献求助10
15秒前
yzy发布了新的文献求助10
17秒前
17秒前
Akim应助友好高山采纳,获得10
18秒前
18秒前
隐形曼青应助谦让的不乐采纳,获得10
18秒前
19秒前
李健的小迷弟应助李LLL采纳,获得10
21秒前
JamesPei应助Alien采纳,获得10
21秒前
illusion发布了新的文献求助10
21秒前
机智的靖荷关注了科研通微信公众号
22秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7280312
求助须知:如何正确求助?哪些是违规求助? 8901460
关于积分的说明 18828852
捐赠科研通 6952305
什么是DOI,文献DOI怎么找? 3207336
关于科研通互助平台的介绍 2377633
邀请新用户注册赠送积分活动 2182399